| Name | CC-401 Hydrochloride |
| Description | CC-401 Hydrochloride (CC401 HCl) is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor (Ki of 25 to 50 nM.)with potential antineoplastic activity. |
| Animal Research | To assess the efficacy of JNK signaling inhibition by CC-401 in anti-angiogenic and oxaliplatin combination therapy in a mouse xenograft model, adult (8-10 weeks of age) female severe combined immunodeficient mice (C.B.17 SCID) were used.?To generate tumors, HT29 cells (1 × 10^6 cells) were injected subcutaneously into the left flank of the mice.?When the tumors reached approximately 200 mm^3, mice were divided into eight groups (eight mice per group) for treatment with bevacizumab , oxaliplatin, CC401, and the appropriate combinations of bevacizumab, oxaliplatin and CC-401.?Mice in the bevacizumab treatment group received 5 mg/kg of bevacizumab by intraperitoneal injection every 3 days for 21 days.?The oxaliplatin treatment group was injected intraperitoneally with 5 mg/kg oxaliplatin per week for 2 weeks.?The CC-401 treatment group was injected intraperitoneally 25 mg/kg for every 3 days.?The combination treatment groups received bevacizumab (every 3 days, 5 mg/kg), oxaliplatin (weekly for 2 weeks, 5 mg/kg), and CC-401 (every 3 days, 25 mg/kg).?The control group received saline intraperitoneally.?Tumor volume and body weight were measured every 3 days.?Tumor volume was calculated using the formula V = AB^2/2, where A is the largest diameter and B is the smallest diameter.?Tumor growth delay was calculated as the difference in the time for control and treated tumors to grow from 200 to 800 mm^3.?For tumor growth delay calculations, mice were continued to receive treatments till the tumor volume reached 800 mm^3.?For immunohistochemistry mice were sacrificed after treatments on day 9 for tumor processing and staining. |
| In vitro | CC-401 in combination with chemotherapy demonstrates synergism in colon cancer cell lines, although synergy is not always hypoxia specific.?A more detailed analysis focused on HT29 and SW620 (responsive), and HCT116 (nonresponsive) lines.?In HT29 and SW620 cells, CC-401 treatment results in greater DNA damage in the sensitive cells. |
| In vivo | In vivo, potentiation of bevacizumab, oxaliplatin, and the combination by JNK inhibition was confirmed in HT29-derived mouse xenografts, in which tumor growth delay was greater in the presence of CC-401.?Finally, stable introduction of a dominant negative JNK1, but not JNK2, construct into HT29 cells rendered them more sensitive to oxaliplatin under hypoxia, suggesting differing input of JNK isoforms in cellular responses to chemotherapy. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 100 mg/mL (235.33 mM)
|
| Keywords | CC 401 Hydrochloride | CC-401 | Inhibitor | JNK | CC401 Hydrochloride | CC 401 | CC401 | inhibit | CC-401 Hydrochloride |
| Inhibitors Related | JNK-IN-13 | Urolithin B | Astragaloside IV | SKLB-163 | SP600125 | (-)-Bornyl acetate | Anisomycin | SR-3306 | (E)-Ferulic acid methyl ester | Bentamapimod | Ginsenoside Re | TCS JNK 5a |
| Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Pain-Related Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
